CLEC2D and prostate cancer: Besides NHLs and gliomas, LLT1 was reported on hormone-refractory and sensitive prostate cancer cell lines and prostate cancer tissues (85), on triple-negative breast cancer cell lines (86) and on a colon cancer cell line (87).